ArticleOncology letters2020
Effect of nalbuphine on patient controlled intravenous analgesia after radical resection of colon cancer.
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 10 citations in OpenAlex.
- Comparison of intravenous nalbuphine and sufentanil on the median effective effect-site concentration of propofol to attenuate the response to cervical dilation during hysteroscopy: a double-blind, dose-response study.BMC anesthesiology · 2025Trial
- Nalbuphine alleviates inflammation by down-regulating NF-κB in an acute inflammatory visceral pain rat model.BMC pharmacology & toxicology · 2022Article
- The role of intravenous lidocaine infusion in enhanced recovery after laparoscopic renal surgeries: A randomized control trial.Journal of anaesthesiology, clinical pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effect of nalbuphine on patient-controlled intravenous analgesia (PCIA) after radical resection of colon cancer was explored. Retrospective analyses of 100 patients who underwent elective laparoscopic radical resection of colon cancer in Xiang Yang No. 1 People's Hospital, Hubei University of Medicine from June 2014 to December 2016 were made. Forty-seven patients were treated with nalbuphine as experimental group and 53 cases were treated with morphine as control group. All patients received PCIA after surgery. According to visual analogue scale (VAS), pain degree at 2, 4, 8, 12 and 24 h after surgery, total dosage of analgesia pump, total times and effective times of pressing were evaluated. Analgesic satisfaction rate, and adverse reactions such as nausea, vomiting, dizziness and headache at the same time were observed and recorded. The postoperative VAS in the experimental group was evidently lower than that in the control group (P<0.05) at 8, 12 and 24 h after surgery, which was statistically significant. There was no significant difference in postoperative VAS between experimental group and control group at 2 and 4 h after surgery (P>0.05). The incidence of adverse reactions to nausea and vomiting in the experimental group was low. There was no significant difference in the total dosage of analgesia pump, total times and effective times of pressing and analgesic satisfaction rate (P>0.05). After laparoscopic radical resection of colon cancer, nalbuphine is effective in PCIA, with low incidence of adverse reactions and high safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.